Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1989 2
1990 4
1991 6
1992 3
1993 7
1994 2
1995 7
1996 7
1997 14
1998 5
1999 7
2000 15
2001 19
2002 31
2003 23
2004 24
2005 55
2006 55
2007 61
2008 83
2009 125
2010 130
2011 164
2012 202
2013 231
2014 271
2015 249
2016 186
2017 146
2018 183
2019 228
2020 232
2021 281
2022 314
2023 238
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

3,221 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for 't and di[au]
Your search for ‘t Zandt DI[au] retrieved no results
Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M, Zhai Y, Chang Y, Pan C, Li G, Kahlert UD, Zhang W. Di W, et al. Cancer Sci. 2022 Feb;113(2):756-769. doi: 10.1111/cas.15236. Epub 2021 Dec 24. Cancer Sci. 2022. PMID: 34881489 Free PMC article.
In addition, CD161 played an essential role in inhibiting the cytotoxicity of T cells in glioma patients. During the process of gliomagenesis, the expression of CD161 on different lymphocytes dynamically evolved. ...Meanwhile, CD161 promoted the progression and evolution o …
In addition, CD161 played an essential role in inhibiting the cytotoxicity of T cells in glioma patients. During the process of gliom …
cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy.
Li W, Lu L, Lu J, Wang X, Yang C, Jin J, Wu L, Hong X, Li F, Cao D, Yang Y, Wu M, Su B, Cheng J, Yang X, Di W, Deng L. Li W, et al. Among authors: di w. Sci Transl Med. 2020 Jun 24;12(549):eaay9013. doi: 10.1126/scitranslmed.aay9013. Sci Transl Med. 2020. PMID: 32581136
We demonstrated that the cGAS-STING cascade in adoptively transferred CD8(+) T cells was essential for antitumor immune responses in the context of T cell therapy in mice. ...In addition, genomic DNA was selectively enriched in the cytosol of mouse CD8(+) T c …
We demonstrated that the cGAS-STING cascade in adoptively transferred CD8(+) T cells was essential for antitumor immune responses in …
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X, Luo H, Shi B, Di S, Sun R, Su J, Liu Y, Li H, Jiang H, Li Z. Wu X, et al. Among authors: di s. Mol Ther. 2019 Aug 7;27(8):1483-1494. doi: 10.1016/j.ymthe.2019.04.020. Epub 2019 Apr 29. Mol Ther. 2019. PMID: 31078430 Free PMC article.
Our previous study indicated that GPC3-targeted chimeric antigen receptor (CAR) T cell therapy has a high safety profile in patients with hepatocellular carcinoma (HCC). ...Thus, this study applied two of the most commonly used mouse models for CAR T cell research a …
Our previous study indicated that GPC3-targeted chimeric antigen receptor (CAR) T cell therapy has a high safety profile in patients …
MEF2C promotes M1 macrophage polarization and Th1 responses.
Zhao X, Di Q, Liu H, Quan J, Ling J, Zhao Z, Xiao Y, Wu H, Wu Z, Song W, An H, Chen W. Zhao X, et al. Among authors: di q. Cell Mol Immunol. 2022 Apr;19(4):540-553. doi: 10.1038/s41423-022-00841-w. Epub 2022 Feb 22. Cell Mol Immunol. 2022. PMID: 35194174 Free PMC article.
Large-scale multiplexed mosaic CRISPR perturbation in the whole organism.
Liu B, Jing Z, Zhang X, Chen Y, Mao S, Kaundal R, Zou Y, Wei G, Zang Y, Wang X, Lin W, Di M, Sun Y, Chen Q, Li Y, Xia J, Sun J, Lin CP, Huang X, Chi T. Liu B, et al. Among authors: di m. Cell. 2022 Aug 4;185(16):3008-3024.e16. doi: 10.1016/j.cell.2022.06.039. Epub 2022 Jul 22. Cell. 2022. PMID: 35870449 Free article.
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Yu KD, et al. Among authors: di gh. JAMA Oncol. 2020 Sep 1;6(9):1390-1396. doi: 10.1001/jamaoncol.2020.2965. JAMA Oncol. 2020. PMID: 32789480 Free PMC article. Clinical Trial.
RESULTS: A total of 647 patients (mean [SD] age, 51 [44-57] years) with operable TNBC were randomized to receive CEF-T (n = 322) or PCb (n = 325). At a median follow-up of 62 months, DFS time was longer in those assigned to PCb compared with CEF-T (5-year DFS, 86.5% …
RESULTS: A total of 647 patients (mean [SD] age, 51 [44-57] years) with operable TNBC were randomized to receive CEF-T (n = 322) or P …
Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity.
Lu Y, Zhao Q, Liao JY, Song E, Xia Q, Pan J, Li Y, Li J, Zhou B, Ye Y, Di C, Yu S, Zeng Y, Su S. Lu Y, et al. Among authors: di c. Cell. 2020 Mar 19;180(6):1081-1097.e24. doi: 10.1016/j.cell.2020.02.015. Epub 2020 Mar 5. Cell. 2020. PMID: 32142650 Free article.
By employing B-cell-specific deletion mice, we showed that ICOSL in B cells boosts anti-tumor immunity by enhancing the effector to regulatory T cell ratio. The signature of ICOSL(+) B cells is imprinted by complement-CR2 signaling, which is triggered by immunogenic cell d …
By employing B-cell-specific deletion mice, we showed that ICOSL in B cells boosts anti-tumor immunity by enhancing the effector to regulato …
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M, Huntington SF, Olszewski AJ. Di M, et al. Oncologist. 2021 Feb;26(2):120-132. doi: 10.1002/onco.13610. Epub 2020 Dec 9. Oncologist. 2021. PMID: 33230948 Free PMC article. Review.
In the relapsed or refractory setting, patients who are not candidates for stem cell transplantation can benefit from newly approved options including polatuzumab vedotin-based combinations or tafasitamab plus lenalidomide, which may have higher efficacy and/or lower toxicity tha …
In the relapsed or refractory setting, patients who are not candidates for stem cell transplantation can benefit from newly approved options …
Lactylated Histone H3K18 as a Potential Biomarker for the Diagnosis and Predicting the Severity of Septic Shock.
Chu X, Di C, Chang P, Li L, Feng Z, Xiao S, Yan X, Xu X, Li H, Qi R, Gong H, Zhao Y, Xiao F, Chang Z. Chu X, et al. Among authors: di c. Front Immunol. 2022 Jan 6;12:786666. doi: 10.3389/fimmu.2021.786666. eCollection 2021. Front Immunol. 2022. PMID: 35069560 Free PMC article. Clinical Trial.
RESULTS: Lactylation was found to be an all-protein post-translational modification and was detected in PBMCs from both healthy volunteers and critically ill patients, with a significantly higher relative density in shock patients (t=2.172, P=0.045). H3K18la was expressed …
RESULTS: Lactylation was found to be an all-protein post-translational modification and was detected in PBMCs from both healthy volunteers a …
A narrative review of tissue-resident memory T cells and their role in immune surveillance and COVID-19.
Chen L, Wei B, Di DL. Chen L, et al. Among authors: di dl. Eur Rev Med Pharmacol Sci. 2022 Jun;26(12):4486-4496. doi: 10.26355/eurrev_202206_29088. Eur Rev Med Pharmacol Sci. 2022. PMID: 35776050 Free article. Review.
Most effector T cells will undergo programmed apoptosis after an immune response and some of them may become memory T cells. According to the distribution and functional status, the memory T cells can be divided into effector central memory T cells (TC …
Most effector T cells will undergo programmed apoptosis after an immune response and some of them may become memory T cells. A …
3,221 results